anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses application of pholidota chinensis lindl. polysaccharides to preparation of hepatoprotective. Pseudobulbs or whole herb of collected fresh pholidota chinensis lindl. is dried in shade and crushed to obtain coarse pholidota chinensis lindl. powder, water is added according to a material-liquid ratio of 1:10, extraction is performed twice with 1.5h each time by virtue of boiling water, extracting solutions are mixed for concentration, extraction is performed  many times with chloroform and n-butanol in a proportion of 4:1 by adopting a Sevag method to obtain supernatant in which proteins are removed, 95 percent ethanol is added to make the ethanol content reach 80 percent, ethanol precipitation is performed on the mixed solution in a 4 DEG C refrigerator for 12h, suction filtration is performed, and filter residues are washed sequentially with ethyl ether, acetone and anhydrous ethanol to obtain crude pholidota chinensis lindl. polysaccharides; the crude pholidota chinensis lindl. polysaccharides are dissolved in water, the obtained solution is loaded into a DE52 type resin chromatographic column subjected to pretreatment with a phosphate buffer solution with pH of 7.5, stands overnight, and is eluted with distilled water at the flow velocity of 1.2ml/min, and eluent is combined and freeze-dried to obtain the pholidota chinensis lindl. polysaccharides. The liver protecting effects of the pholidota chinensis lindl. polysaccharides are developed, and a research foundation is laid for further deep development of the pholidota chinensis lindl. polysaccharides.
A harmless cancer vaccine is made from cancer cells with extracellular proteins including self-recognition molecular patterns being digested by a proteinase. The cancer vaccine is used to vaccinate an individual to induce immune responses against cancer cells systemically. Cancer cells become harmless when they are digested by Tumorase™. Some proteinases including trypsin cannot kill cancer cells completely and treated cancer cells need to be further processed in order to be harmless and effective. Cancer cells may be from tissue-cultured human or animal cancer cell lines or cancer patients directly. Cancer vaccine vaccinated individuals produce cancer vaccine specific immune responses against cancer cells. Immune response components may be isolated and used to fight against cancer for a cancer patient with a suppressed immune system. Cancer vaccine specific immune components may include cancer vaccine specific polyclonal antibodies, B-cells, T-cells, natural killer cells, monocytes, macrophages and other lymphocytes.
The efficacy of GONAL-F in ART, was evaluated in a randomized,open-label, multicenter, active-controlled trial conducted ith the U.S, in ovulatory, infertile women undergoing stimulation of multiple follicles for In Vitro Fertilization (IVF) and Embryo Transfer (ET). All women received a gonadotrophin releasing hormone (GnRH) agonist for pituitary down-regulation before randomization and administration of GONAL-F (n=56) or a comparator urofollitropin product (n=58). The primary efficacy endpoint was the number of mature pre-ovulatory follicles on the day of hCG administration. The trial was not powered to demonstrate differences in secondary outcomes.

Treatment outcomes for a single IVF cycle with controlled stimulation with GONAL-F are summarized in Table 6.

For the 11 woman in the GONAL-F group who achieved clinical pregnancy, 36.3% did not reach a term pregnancy, 36.3% had singleton births and 27.3% had multiple births.

An additional randomized, open-label, multinational, multicenter study in ovulatory infertile women was conducted in non-U.S. countries. Women were randomized to receive either GONAL-F by subcutaneous administration (60 women) or urofollitropin by intramuscular administration (63 women) after down-regulation of the pituitary with a GnRH agonist. The primary efficacy parameter was the number of mature pre-ovulatory follicles on the day of hCG administration. Results over a single IVF cycle for the primary efficacy outcome of mature pre-ovulatory follicles on the day of hCG administration were similar to the primary efficacy results presented in Table 6 for the U.S.ART trial.
Uncontrolled asthma is a risk factor for a serious outcome, including death, in anaphylaxis. Ensure patients with asthma have their asthma under control prior to initiation of PALFORZIA.

PALFORZIA should be temporarily withheld if the patient is experiencing an acute asthma exacerbation. Following resolution of the exacerbation, resumption of PALFORZIA should be undertaken cautiously [see Dosage and Administration (2.5)] . Re-evaluate patients who have recurrent asthma exacerbations and consider discontinuation of PALFORZIA. PALFORZIA has not been studied in subjects with severe asthma, persistently uncontrolled asthma, or patients on long-term systemic corticosteroid therapy.
Plerixafor 0.12 mg/kg SC will be administered in the evening, 11 hours prior to initiation of apheresis. G-CSF will be administered in the morning at 10 mcg/kg SC for 4 days prior to apheresis.
Percutaneous electrical nerve stimulation applied to the ear x 4 over a 4 week period. The device is placed over the area of the ear and worn home continuously for a 5-day period, during which time it stimulates at a pre-set on/off duty cycle. At each in-person visit, the device is replaced until the device has been placed 4 times. The stimulation delivered is below the threshold of sensory perception.
A method for enhanced PhotoDynamic Therapy (PDT) treatments by applying dendrimer-photosensitizer complexes to bring multiple phototosensitizer moieties to a treatment site is provided. Photosensitizers are covalently coupled to the peripheral bonding places of dendrimers and are being separated in one or more successive cycles. Tetrapyrroles are the photosensitizers employed. In one embodiment the complex is also bound to an antibody or antibody fragment, which aids in targeting the complex to a desired treatment site. After application, the photosensitizers are released, at the treatment site, from the complexes by either light, chemical, or a combined light/chemical effect. Generally the photosensitizers develop their full photodynamic activity as free molecules after being released from the complex.  More than one type of photosensitizer may be bound in the complexes. Release and/or activation may be done in a single step or with repeated steps.
The final subject in Cohort 1 completed the study on 19-Nov-2013 (LSLV date). Because the study analyses were novel and exploratory, they required extensive analyses by study team and external experts. As a result of this analysis it was determined on 21-July-2014 that the data from Cohort 1 were sufficiently definitive and that enrollment of Cohort 2 would not be justified. Since this decision resulted in the LSLV for Cohort 1 becoming the LSLV for the study, the full data analysis and reporting is not projected to be complete within 12 Months of LSLV. The final analysis and final reporting is planned to be completed on 18-Feb-2015. Results for this data are anticipated to be released in April 2015.
A Phase 3, randomized, placebo-controlled, double-masked, parallel study in healthy subjects performed in the US. It is designed to evaluate the ocular safety of one dose of AG-920 compared to placebo. I). In this study, subjects who provide informed consent and fulfill all the inclusion criteria and none of the exclusion criteria will be randomized in a 2:1 ratio to receive one dose of AG-920 or identical looking placebo into one (study) eye. A subset of subjects will undergo endothelial cell count (ECC) evaluations.

Each dose of AG-920 or placebo will consist of two drops in the study eye. After the completion of dosing, subjects will undergo a series of eye exams that will be documented. Investigational medicinal product (IMP) dosing will be performed by the study staff.
Study participants will be administered in 2GBq in 3 fractions corresponding to ⅓ full dose activity (0.67 GBq for the 2.0 GBq dose level). The 1st fraction of 131I-IPA will be administered as above, 1- 3 days prior to 1st XRT. The 2nd and 3rd 131I-IPA fractions will be administered after 5-9 XRT fractions (subject to investigator's discretion and day of IMP administration) following the previous 131I-IPA fraction. The remainder of XRT fractions will be given following the 3rd 131I-IPA fraction.
Participants will generate positive recent past events that have happened to them at five time points in the recent past (last night from 7pm-10pm, yesterday between 4pm-7pm, yesterday between 1pm-4pm, yesterday from 10am-12pm, yesterday between 7am-10am, the night before last between 7pm-10pm, and evening before last between 4pm-7pm). Participants will be reminded of these events using cues throughout the study and instructed to think about these cues as they make their decisions.
OBJECTIVE: The purpose of this study was to evaluate the feasibility of a randomized controlled trial investigating the effectiveness of a multimodal program (PAT-Back) compared to best practice advice on pain and disability in older adults with chronic low back pain (LBP) in primary care.
METHODS: This feasibility study took place in Fortaleza, Northeast Brazil. The PAT-Back intervention consisted of a program including exercises, pain education, and motivational text messages for the in-home component. The control group received an evidence-based educational booklet. Feasibility outcomes were recruitment, adherence and retention rates, level of difficulty of the education and intervention content, perception of utility of mobile technology, and adverse events. The feasibility criteria were previously defined.
RESULTS: A total of 248 people were screened, of which 46 older adults were eligible. The retention rate was high (100% in the PAT-Back group and 95% in the control group). The adherence rate to intervention was partially met (60%), whereas the adherence rate to unsupervised exercises was adequate (75%), and perception about safety to perform home exercise was partially acceptable (70%) in the PAT-Back group. In addition, 100% of older adults reported which text messages motivated them to perform the exercises in the PAT-Back group. Difficulty reported by participants in understanding and performing the intervention was small in both groups. Six participants reported transient adverse events in both groups.
CONCLUSION: Older adults accepted both interventions. Results demonstrated that the program is feasible, although minor changes targeting adherence and safety in home exercise are needed.
IMPACT: This feasibility study supports progression to a full trial investigating the effectiveness of a multimodal program (PAT-Back) on pain and disability in older adults with chronic LBP within a primary health care setting in low to middle income countries where such data from the older population are scarce and the burden of LBP is increasing.
Rhodium tetraphenylporphyrin-aza-BODIPY-based near infrared compounds have a structure shown in the specification. Compared with the prior art, a preparation method of the compounds is characterized in that Rhodium tetraphenylporphyrin-aza-BODIPY compounds {Rh(ttp)-aza-BODIPY} compounds are synthesized in a Rh-C bond axial connection mode. The compounds simultaneously have the optical properties of a transition metal rhodium and aza-BODIPY. The center metal Rh<III> has a unique d<6> electron configuration, so the compounds have a very effective intersystem crossing coefficient, and generate long life phosphorescent light and singlet oxygen. The aza-BODIPY has very strong absorption in the near infrared region, and can successfully shift the absorption wavelength of the compounds into the near infrared region to make the compounds widely applied. The invention also discloses the preparation method of the compounds.
Subject matter of this application is obtaining of active principle and pharmaceutical preparation from herbal mixture comprising following dried and ground ingredients: plant of centaury (Centaurii umbellatum, Gentianaceae) 10-15% by weight (wt.) root of dandelion (Teraxacum officinale, Asteraceae) 6-12 % by wt. fruit of juniper (Juniperi communis L, Cupresaceae) 5-8 % by wt. plant of nettle (Urticae dioica L, Urticaceae) 5-10 % by wt. root of nettle (Urticae dioica L, Urticaceae) 5-10 % by wt. root of chicory (Cichorium intybus L, Cichoriaceae) 12- 20 % by wt. leaf of black mulberry (Morus nigra L, Moraceae) 5-10 % by wt. flower of yarrow (Achilleae millefolium L, Asteraceae) 2-5 % by wt. leaf of bilberry (Vaccinium myrtillus L, Ericaceae) 4-10 % by wt. pod of beans (Phaseolus vulgaris L, Fabaceae) 10-20 % by wt. and root of valerian (Valeriana officinalis L, Valerianaceae) 5-10 % by wt wherein each percentage refers to the total mass of the dried ingredients in the composition, at room temperature, extraction of this mixture in a covered container at the room temperature and pressure for 28 days, decantation of upper layer, filtration of lower layer comprising increasing the density of the herbal mixture by whirling spray granulation with spraying with gas under pressure 1-3 barr, through 30-40 minutes, with provision that temperature of anhydrous gas has to be at least 10° C higher than entering temperature of tincture.
Part 1: Subjects will receive prescribed doses of Arm 3 probes on Day -1, followed by the first enasidenib dose on Day 1. Subjects will continue to take enasidenib once daily for 27 more days. On Day 28, subjects will receive the Arm 3 probes again together with the Day 28 dose of enasidenib. Part 2: the subjects continue to receive daily doses of enasidenib for the next 28 days (equivalent to a cycle). The subject will continue in subsequent cycles until the end of the study (28 months) or termination.
In a Japanese chemical factory, lung diseases such as pneumoconiosis have been reported among workers handling cross-linked water-soluble acrylic acid polymers (CWAAP). Our previous study reported that a single intratracheal administration of CWAAP induces acute inflammation and fibrosis. In this study, we investigated the effects of multiple intratracheal administrations of CWAAP on inflammatory responses and pulmonary fibrosis along with inducible bronchus-associated lymphoid tissues (iBALT) formation, which is involved in allergic inflammation. Male F344 rats (190-200 g) received single or multiple intratracheal administrations of phosphate-buffered saline (PBS) or CWAAP. To assess inflammatory responses and pulmonary fibrosis, immunohistochemical and histological staining was performed. CD68, CD163, CD169, TGF-β, and collagen I positive cells/areas in the lungs of the CWAAP-group rats were significantly increased than those in the PBS group. Furthermore, the number of iBALT structures, CD4 + T cells, along with CD19, PAX5, IL-4, GATA-3, T-bet, and IgE-positive cells in the terminal bronchioles and blood vessels of the lungs were significantly increased in the CWAAP group. Moreover, pulmonary fibrosis, iBALT formation, and levels of specific IgG were significantly increased in rats who received multiple intratracheal administrations of CWAAP compared to those with single intratracheal administration. Multiple intratracheal administrations of CWAAP potentiated the classical fibrotic pathway (M2 macrophage-TGF-β-collagen I) more potently than single intratracheal administration. Furthermore, it was possible that iBALT was formed around terminal bronchioles and blood vessels and the number of immune cells was increased, resulting in enhanced allergic inflammation and pulmonary fibrosis.
Single IV infusion of placebo for tanezumab on Day 1. Maintained on baseline opioid regimen.
Postanesthesia paradoxical vocal cord motion disorder (PVCMD) is often benign. However, if not recognized, PVCMD can lead to unnecessary treatments. Our patient had 3 different surgeries over a period of 20 months. The first episode of PVCMD occurred after a shoulder surgery, and the patient was reintubated. PVCMD was correctly diagnosed and treated successfully with reassurance after an ulnar nerve decompression. The third episode of PVCMD occurred after a cervical fusion surgery. Prevertebral edema from surgery further compromised the airways. Our case demonstrates the challenges of identifying and managing perioperative PVCMD, especially when surgical complications confound the airway management.
PROBLEM TO BE SOLVED: To obtain a bathing agent composition containing tea leaves of Eucommia ulmoides or an extract of leaves of Eucommia ulmoides and excellent in beauty culture effect and moisture-retaining effect. SOLUTION: This composition contains 20-60wt.% of tea leaves of Eucommia ulmoides of the family Eucommiacea or 5-30wt.% of an extract taken out from a resin or leaves of Eucommia ulmoides. Besides, inorganic salts (ex; sodium hydrogencarbonate) are used as a main agent, a coloring matter, an enzyme, a perfume, a germicide. etc., are added to prepare a powdery or granular bathing agent and also a softener (ex: lanolin) is used as a main agent, and a coloring matter, an enzyme, a perfume, a germicide, etc., are added thereto to prepare a liquefied bathing agent. The tea leaves of Eucommia ulmoides are obtained by smothering, roasting, crumpling and drying a crude drug of Eucommia ulmoides.  Moreover, the extract of Eucommia ulmoides is obtained by extracting a bark or leaves of Eucommia ulmoides with water, particularly hot water, excluding impurities by allowing the obtained extract to pass through an ultrafiltration film and further allowing it to pass through a reverse osmosis film.
The goal of this study is to determine if SCPBs provide more pain control than local infiltrate of anesthetic for internal jugular venous cannulation. The investigators hypothesis that patients who receive the SCPB will have a lower VAS rating on average than those who receive local infiltration following internal jugular venous cannulation. To test this, the investigators will be approaching eligible patients for inclusion in a research study. If the patients consent, the patients will be randomly assigned the standard of care treatment or the SCPB. The investigators will then ask the patients to rate pain following insertion of the central line. The investigators will also evaluate different aspects of the patient's hospital course to evaluate their outcomes.
Insulin resistance and diabetes are major disease modifiers in chronic hepatitis C, as they increase liver fibrogenesis and reduce the rate of response to antivirals. Regarding the latter, a previous study showed that a sustained virological response (SVR) occurred in about one third of patients with genotype 1 and insulin resistance (measured as homeostasis assessment of insulin resistance, HOMA-IR \> 2) vs. two thirds of genotype 1 patients without insulin resistance. These findings were independently confirmed by other studies and extended to non-responders with genotypes 2, 3 and 4. Thus, we suggested that insulin resistance should be corrected in patients with chronic hepatitis C not responding to currently available antiviral treatment, in order to improve response to retreatment. The modalities of this intervention, however, have not been established. In addition, the optimal HOMA-IR score to be attained has not been identified. To assess this point, we planned a prospective, multicenter study to investigate the efficacy and safety of the insulin-sensitizer pioglitazone (ActosTM, Takeda Pharma AG, Lachen, Switzerland) 15 mg QD, added to the pegylated interferon-α2a (PEG-IFN-α2a) (PegasysTM, Roche Pharma Schweiz AG, Reinach, Switzerland) 180 μg QW/ribavirin (CopegusTM, Roche) 1000-1200 mg QD combination therapy in chronic hepatitis C patients who had previously failed to respond (i.e. had detectable serum HCV RNA after 12 weeks of therapy) to a pegylated interferon-α/ribavirin combination without the insulin-sensitizer. All patients had a baseline HOMA-IR score \>2 as additional inclusion criterion, because this was the threshold discriminating responders from non-responders in previous works. Diabetic patients were excluded.
At the end of the fall semester midterm exam, the 'Self-Efficacy Survey in Practices Requiring the Most Commonly Used Skills in Nursing' will be administered. At the end of the semester, students will be asked to fill out the 'Self-Efficacy Survey in Practices Requiring the Most Commonly Used Skills in Nursing'. This scale will measure self-efficacy. At the end of the semester, students will be evaluated with 2 skill applications and skill exam scores to be selected by written exam and lottery method. With these exams, skills and theoretical knowledge will be measured.
The activity of anti-CD19 chimerci antigen receptor (CAR) T-cell therapy in chronic lymphocytic leukemia (CLL) with Richter's transformation (RT) to aggressive large B-cell lymphoma (LBCL) is largely unknown. In a multicenter retrospective study, we report the safety and efficacy of CAR T-cell therapy in patients with RT (N=30) compared to patients with aggressive B-cell lymphoma (N=283) and patients with transformed indolent non-Hodgkin lymphoma (iNHL) (N=141) between April 2016 and January 2023. Two-thirds of patients received prior therapy for CLL before RT and 89% of them received B-cell receptor and B-cell lymphoma 2 inhibitors. Toxicities of CAR T-cell therapy in RT were similar to other lymphomas, with no fatalities related to cytokine release syndrome or immune effector-cell associated neurotoxicity synderome. The 100-day overall response rate and complete response rates in patients with RT were 57% and 47%, respectively. With a median follow-up of 19 months, the median overall survival (OS) was 9.9 months in patients with RT compared to 18 months in de novo LBCL and not reached in patients with transformed iNHL. The OS at 12 months was 45% in patients with RT compared with 62% and 75% in patients with de novo LBCL and transformed iNHL, respectively. In a multivariate analysis, worse OS was associated with RT histology, elevated lactate dehydrogenase, and more prior lines of therapy. CAR T-cell therapy can salvage a proportion of patients with CLL and RT exposed to prior targeted agents; however, efficacy in RT is inferior compared to de novo LBCL and transformed iNHL.
PURPOSE:To facilitate molding without requiring operation for pH adjustment, etc., by adding water, a deflocculant and dispersant to a mixture composed of tricalcium phosphate, calcium carbonate and additive to prepare a slurry, putting the slurry into a gypsum mold and heating a slip cast molding piece, thereby obtaining the sintered body of apatite. CONSTITUTION:The water, the deflocculant and the dispersant is added to the mixture composed of the tricalcium phosphate, the calcium carbonate and the additive to prepare the slurry and the slurry is put into the gypsum mold and is slip cast molded, then the slip cast molding piece is heated, by which the sintered body of the apatite is obtd. The ratio of the tricalcium phosphate to the calcium carbonate is specified to 3:1 by molar ratio and the ratio of the water is specified to <=50% by weight. The tricalcium phosphate is formed of a mixture composed of an alpha type and a beta type and the mixing ratio thereof is specified to the alpha type: beta type=0:1 to 3:1. Further, volatile camphor is used for the additive and the ratio thereof is specified to >=4% by the weight ratio to the slip. The heating temp. of the molded piece is specified to 600 to 1200 deg.C.